Auger electron therapy using In-111-labelled F3 peptide

Auger electron therapy using In-111-labelled F3 peptide

Detalhes bibliográficos
Main Authors:	Cornelissen, B, Waller, A, Target, C, Kersemans, V, Smart, S, Vallis, K
Formato:	Journal article
Publicado em:	2011

Registos relacionados

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
Por: Cornelissen, B, et al.
Publicado em: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
Por: Cornelissen, B, et al.
Publicado em: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
Por: Cornelissen, B, et al.
Publicado em: (2012)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Por: Cornelissen, B, et al.
Publicado em: (2011)

Targeting the nucleus: an overview of Auger-electron radionuclide therapy.
Por: Cornelissen, B, et al.
Publicado em: (2010)

Auger electron radionuclide therapy utilising F3 peptide to target the nucleolus
Por: Hillyar, C
Publicado em: (2015)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
Por: Cornelissen, B, et al.
Publicado em: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Por: Costantini, D, et al.
Publicado em: (2007)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
Por: Cornelissen, B, et al.
Publicado em: (2006)

Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy
Por: Terry, S, et al.
Publicado em: (2012)

Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
Por: Terry, S, et al.
Publicado em: (2012)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
Por: Costantini, D, et al.
Publicado em: (2008)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Por: Costantini, D, et al.
Publicado em: (2010)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Por: Bailey, K, et al.
Publicado em: (2007)

Moleculary targeted auger electron radiation therapy for breast cancer: A clinical trial.
Por: Vallis, K, et al.
Publicado em: (2004)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Por: Cornelissen, B, et al.
Publicado em: (2009)

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Por: Kersemans, V, et al.
Publicado em: (2008)

Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells
Por: Kersemans, V, et al.
Publicado em: (2006)

SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo
Por: Song, L, et al.
Publicado em: (2016)

Cell penetrating peptides for in vivo molecular imaging applications.
Por: Kersemans, V, et al.
Publicado em: (2008)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
Por: Chen, P, et al.
Publicado em: (2001)

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
Por: Andrey A. Rosenkranz, et al.
Publicado em: (2018-11-01)

Auger electrons for cancer therapy – a review
Por: Anthony Ku, et al.
Publicado em: (2019-10-01)

Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy
Por: Kersemans, V, et al.
Publicado em: (2010)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Por: Reilly, R, et al.
Publicado em: (2006)

Preparation and Evaluation of Thermosensitive Liposomes Encapsulating I-125-Labeled Doxorubicin Derivatives for Auger Electron Therapy
Por: Mohamed Elsaid Nasr Elghobary, et al.
Publicado em: (2023-02-01)

Imaging DNA damage response (DDR) during oncogenesis
Por: Cornelissen, B, et al.
Publicado em: (2013)

Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
Por: Cornelissen, B, et al.
Publicado em: (2007)

Single cell S-value calculations of a stochastic cascade model for Auger-electron emitting radionuclides
Por: Vallis, K, et al.
Publicado em: (2016)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
Por: Sadaf Aghevlian, et al.
Publicado em: (2020-11-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab.
Por: Patel, N, et al.
Publicado em: (2017)

Augers and auger bits
Por: 8096 British Standards Institution

18F-trifluoromethylation of unmodified peptides with 5-18F-(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate
Por: Verhoog, S, et al.
Publicado em: (2018)

Scanning auger electron microscopy /
Por: Prutton, M, et al.
Publicado em: (2006)

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Por: Cornelissen, B, et al.
Publicado em: (2008)

Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy
Por: Bart Cornelissen, et al.
Publicado em: (2010-03-01)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical
Por: Cornelissen, B, et al.
Publicado em: (2012)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
Por: Cornelissen, B, et al.
Publicado em: (2012)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
Por: Neel Patel, et al.
Publicado em: (2017-05-01)

Internalization of Auger electron-emitting isotopes into cancer cells: A method for spatial distribution determination of equivalent source terms
Por: Vallis, K, et al.
Publicado em: (2016)